The Alger Small Cap Focus Fund (Class A shares) outperformed the Russell 2000 Growth Index in Q3 2026. Key contributors to the fund's positive performance included biotech companies Forte Biosciences, Twist Bioscience, and Adaptive Biotechnologies. On the other hand, stocks like Cardinal Infrastructure Group, RBC Bearings, and VSE Corporation detracted from returns despite VSE showing strong revenue growth and improved profitability. This performance highlights the fund's focus on growth equity investing and its ability to navigate market changes by investing in innovative sectors.
The Alger Small Cap Focus Fund's Q3 2026 update provides context for readers following health-related growth equities. For readers following health sector stocks, here is Pluang's market snapshot as of Oct 24, 2026 00:21 WIB: out of 150 priced health-sector US stocks, 47 rose and 103 fell. Notable movers include Guardant Health Inc. (GH) at USD 169.12 with a 1-day change of +3.79% and 100% sell order activity, Tilray Brands Inc (TLRY) at USD 2.82 down 3.75% with 56% buy orders, and Adaptive Biotechnologies Corp (ADPT) at USD 25.31 up 3.69% with 100% buy orders and a typical hold time of 37 days on Pluang.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
